Breakthrough Pain — Transient Cancer Pain Flairs

Breakthrough pain is clinically defined as an abrupt, temporary exacerbation of pain experienced by a patient who already has relatively stable and adequately managed background chronic pain. Episodes typically feature a rapid onset, reaching peak intensity within minutes, and generally persist for an average duration of 30 to 60 minutes before gradually resolving.

Clinicians categorise breakthrough pain into distinct sub-types. Incident pain is provoked by specific, identifiable triggers, which can be volitional (such as walking, movement, or coughing) or non-volitional (such as bladder spasms or bowel peristalsis). Spontaneous or idiopathic pain occurs unpredictably without an evident mechanical or physiological trigger. A third form, end-of-dose failure, arises when baseline scheduled analgesics wear off before the next scheduled dose is due.

Uncontrolled breakthrough pain can severely impair a patient's functional independence, emotional well-being, and overall quality of life. It frequently leads to sleep disturbance, heightened anxiety, depression, and avoidance of routine physical activities due to fear of precipitating an episode. Identifying breakthrough pain helps palliative and oncology teams differentiate between inadequately controlled baseline pain and genuine episodic flares, ensuring patients receive the correct combination of background and fast-acting rescue medications.

Breakthrough pain is diagnosed through clinical evaluation rather than laboratory biomarkers. Doctors use validated pain assessment tools, visual analogue scales, and patient pain diaries that record frequency, duration, intensity, triggers, and relief patterns. Imaging studies, such as CT or MRI scans, may be performed to determine whether an episode is caused by new structural complications, such as impending bone fracture or spinal cord compression.

Breakthrough pain can occur in any advanced malignancy, but it is especially prevalent in cancers involving bone metastases, such as breast, prostate, lung, and multiple myeloma, where movement can trigger intense mechanical pain. It is also frequent in advanced head and neck cancers, gastrointestinal cancers, and pelvic malignancies involving visceral or neuropathic nerve infiltration.

Management requires rapid-onset rescue analgesics alongside baseline maintenance opioids. Rapid-onset transmucosal fentanyl formulations (sublingual tablets, lozenges, or nasal sprays) absorb quickly through mucosal membranes, mimicking the rapid onset of the pain episode. Immediate-release oral morphine or oxycodone are also commonly prescribed. Non-pharmacological therapies, nerve blocks, palliative radiotherapy for bone metastases, and physical therapy are integrated to reduce flare frequency.